Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.
Tedizolid, a novel oxazolidinone antibacterial, was administered to Long Evans rats by oral gavage once daily for up to 9 months at doses near the maximum tolerated dose (MTD) to evaluate for potential neurotoxicity. Mean plasma exposures of tedizolid at the low-, medium-, and high-dose levels (7.5, 15, and 30 mg/kg of body weight/day for males; 2.5, 5, and 10 mg/kg/day for females) were similar between males and females and were 1.8-, 3.9-, and 8.0-fold greater than exposures in patients at the therapeutic dose (200 mg once daily). Evaluated endpoints included survival, clinical observations, body weight, and food consumption. At 1, 3, 6, and 9 months, ophthalmic examinations, functional observational batteries, and locomotor activity measures were conducted, brain weights/sizes were recorded, and perfusion-fixed tissues were collected from 12 rats/sex/group/time point. A detailed morphological assessment was conducted on brain, eyes, optic nerve/tract, spinal cord, peripheral nerves (includes sciatic, sural, tibial, peroneal, trigeminal), and skeletal muscle. At the end of 9 months, less body weight gain was seen in high-dose males (-6.7%) and females (-5.8%) compared with that seen in controls. There were no tedizolid-related adverse neurobehavioral effects or tedizolid-related histopathologic changes in the central/peripheral nervous systems, including the optic nerve. Results of this study indicate that tedizolid was not neurotoxic when administered long term to pigmented rats at doses near the MTD, which were up to 8-fold higher than the human therapeutic exposure.
MSR Pharma Services, Lincolnshire, Illinois, USA.
Michael J
MJ
Schlosser
WIL Research, Ashland, Ohio, USA.
Hiromi
H
Hosako
WIL Research, Ashland, Ohio, USA.
Ann
A
Radovsky
Tox Path Specialists, Frederick, Maryland, USA.
Mark T
MT
Butt
WIL Research, Ashland, Ohio, USA.
Dragomir
D
Draganov
WIL Research, Skokie, Illinois, USA.
Jenifer
J
Vija
Cubist Pharmaceuticals, Lexington, Massachusetts, USA rick.oleson@cubist.com.
Frederick
F
Oleson
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D000069349:Linezolid / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D020258:Neurotoxicity Syndromes / Q000401:mortality*; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D010080:Oxazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D051381:Rats; D020332:Rats, Inbred LEC
D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; D000069349:Linezolid; C515040:tedizolid phosphate